| Objective To observe the effect of early injection of Edaravone dexborneol after intravenous thrombolysis of alteplase on acute ischemic stroke and the effect on MMP-9 and OCLN,as well as to probe the potential mechanism of early injection of Edaravone Dexborneol after intravenous thrombolysis of alteplase on acute cerebral infarction.Methods A total of 90 patients with acute cerebral infarction admitted to the Department of Neurology of our hospital from December 2021 to December 2022 were selected as the research objects.According to the random number table method,the patients were divided into experimental group 45 cases and control group 45 cases.Control group received intravenous alteplase thrombolytic therapy,and the rest received standard treatment.Experimental group was given Edaravone dexborneol injection 15 ml Edaravone dexborneol injection,intravenously,twice a day,early after intravenous thrombolysis of alteplase(within 24 hours),for 10 days,and the rest were given standard treatment.The standard treatment of the two groups was based on the "Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke 2018",which was applied to improve brain blood supply,anti-platelet aggregation,lipid-lowering plaque stabilization,nerve nutrition,reducing intracranial pressure and other treatments.Before treatment(day 1 of admission),10±2 days and 90±7 days of treatment,changes in Index of Daily living(BI)score,NIHSS score,modified Rankin (m RS)score and the occurrence of adverse events were collected and sorted out.Meanwhile,the levels of serum OCLN and MMP-9(MMP-9)on the 1st day and the10 th ± 2nd day after admission were collected and detected.SPSS26.0 was used for statistical analysis of the data obtained from the experiment.Results1.There was no significant difference in NIHSS scores between the two groups before treatment(P>0.05).The NIHSS scores of the two groups were lower than those before treatment at 10±2 days and 90±7 days after treatment,and the difference was statistically significant(P<0.01),and there were significant differences between the test group and the control group(P<0.05,P<0.01).2.There was no significant difference in m RS Scores between the two groups before treatment(P>0.05).The m RS scores of the two groups were lower than those before treatment at 10±2 days and 90±7 days after treatment and the difference was statistically significant(P<0.01),and there were significant differences between the test group and the control group(P<0.05,P<0.05).3.There was no significant difference in BI scores between the two groups before treatment(P>0.05).The BI scores of the two groups were lower than before treatment at 10±2 days and 90±7 days,and the difference was statistically significant(P<0.01),and there were significant differences between the test group and the control group(P<0.05,P<0.01).4.There was no significant difference in serum MMP-9 and OCLN levels between the two groups before treatment(P>0.05).After treatment,the serum level of MMP-9in the two groups was lower than that before treatment,and the serum level of OCLN was higher than that before treatment,and the differences were statistically significant(P<0.01).The serum levels of MMP-9 and OCLN in the experimental group were significantly lower than those in the control group at 10±2 days after treatment(P<0.05).5.After treatment,the effective rates of the test group and the control group were 95.6% and 77.8%,respectively.The effective rate difference between the two groups was statistically significant(P<0.05).6.Adverse events occurred in both groups during treatment.In the experimental group,there were 2 cases of cerebral hemorrhage transformation and 1 case of gastrointestinal discomfort.In the control group,1 case of cerebral hemorrhage transformed,1 case of gastrointestinal discomfort,and no other adverse events were observed.The incidence of adverse events in the experimental group and the control group were 6.67% and 4.44%,respectively,with no significant difference.Conclusions In patients with acute cerebral infarction,early administration of Edaravone and dexborneol following alteplase thrombolytic therapy is superior to conventional therapy.This therapeutic approach exhibits notable efficacy in reducing neurological deficits and improving long-term prognosis.Early administration of Edaravone dexborneol after thrombolysis may reduce the damage of blood-brain barrier caused by reperfusion injury after vascular recirculation by reducing the level of MMP-9 and OCLN in serum,thus playing a role in brain protection.Additionally,the treatment approach did not result in higher incidences of adverse events,indicating a satisfactory level of safety. |
PDF Full Text Request